Cyclerion Therapeutics Inc (CYCN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) has a cash flow conversion efficiency ratio of -0.173x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.18 Million) by net assets ($6.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cyclerion Therapeutics Inc (CYCN) net asset quality to measure how much of total assets are equity-financed.
Cyclerion Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Cyclerion Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Cyclerion Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
Cyclerion Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cyclerion Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nexted Group Ltd
AU:NXD
|
0.510x |
|
ValOre Metals Corp
V:VO
|
-0.094x |
|
QPR Software Oyj
HE:QPR1V
|
-0.282x |
|
Tae Won Mulsan
KO:001420
|
-0.030x |
|
Vogiatzoglou Systems S.A
AT:VOSYS
|
0.047x |
|
SILVER DOLLAR RES
F:4YW
|
-0.008x |
|
Oceanic Beverages Co Inc
TW:1213
|
0.003x |
|
Mahube Infrastructure Ltd
JSE:MHB
|
0.009x |
Annual Cash Flow Conversion Efficiency for Cyclerion Therapeutics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Cyclerion Therapeutics Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see CYCN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.09 Million | $-3.31 Million | -0.365x | +25.50% |
| 2024-12-31 | $8.85 Million | $-4.33 Million | -0.490x | +73.99% |
| 2023-12-31 | $11.29 Million | $-21.25 Million | -1.882x | +51.56% |
| 2022-12-31 | $10.45 Million | $-40.61 Million | -3.885x | -413.35% |
| 2021-12-31 | $48.25 Million | $-36.52 Million | -0.757x | +37.88% |
| 2020-12-31 | $59.49 Million | $-72.49 Million | -1.218x | -16.50% |
| 2019-12-31 | $97.73 Million | $-102.22 Million | -1.046x | -111.20% |
| 2018-12-31 | $-10.45 Million | $-97.50 Million | 9.335x | -1.53% |
| 2017-12-31 | $-8.57 Million | $-81.22 Million | 9.480x | +28.52% |
| 2016-12-31 | $-6.76 Million | $-49.87 Million | 7.377x | -- |
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular d… Read more